1806-LB: improvement in sensory function and achieving remission of type 2 diabetes mellitus through digital twin technology—A one-year intervention study

Abstract

Introduction and Objectives: Digital twin (DT) platform uses Artificial Intelligence (AI) and Internet of Things, to integrate multi-dimensional data for precision nutrition and health recommendations via the mobile app and by coaches. Remission was defined as A1C levels less than 6.5% without medication for over 3 months. Status of sensory functions were assessed by monofilament test (MF) and vibration perception (VP) in patients on DT platform. Methods: We monitored 181 T2DM patients, across 4 centers, for remission of T2DM, with a focus on participants with sensory neuropathy. Statistical analysis, including the Pearson correlation coefficient, explored the link between HbA1c levels and change in sensory functions. Results: Mean age, duration of diabetes, were 44 years (±8.6) and 3.7 years (±2.7). Mean HbA1c decrease was 3.03 (8.9% to 5.8), indicating significant improvements from baseline to Day 360. 75.69% of the participants (n=137) achieved remission. Sensory function evaluations showed significant improvement: 96.4% (26 of 27) improved touch sensitivity in MF test (p=0.0013), and 63.0% (46 of 73) showed better vibration perception in VP test (p<0.0001). The correlation between remission and sensory test improvements was found to be weak, with MF changes showing a very slight negative correlation (r=-0.0187) and VP changes a slight positive correlation (r=0.0798), indicating that achievement of remission is not a strong predictor of sensory function recovery. Conclusion: DT has a transformative potential for sensory function recovery among T2DM undergoing remission, evidenced by significant improvements in MF and VP tests. However, the minimal correlation between remission and sensory improvement suggests that the recovery of sensory functions in diabetic neuropathy involves a complex interplay of factors, emphasizing the need for comprehensive management approaches and further research into neuropathic recovery mechanisms. Disclosure: P. Shamanna: None. M. Dharmalingam: None. A. Vadavi: None. A. Keshavamurthy: None. S. Bhonsley: None. L. Shah: Employee; Twin Health. M. Panandikar: None. S.R. Joshi: Consultant; Twin Health, Marico, Franco Indian, Zydus Cadila, Glenmark Pharmaceuticals. Other Relationship; Novo Nordisk, Sanofi, MSD, Abbott Nutrition, Abbott, Biocon, Alkem, USV Private Limited, Boehringer-Ingelheim.